There is a grave need for the identification of [[molecular targets]] for therapeutic treatment and [[biomarker]]s as risk predictors for [[hemorrhagic stroke]] [[prevention]]. Based on reported various perturbed angiogenic signaling cascades mediated by the CCM signaling complex (CSC), there have been many proposed candidate drugs, targeting potentially angiogenic-relevant signaling pathways dysregulated by loss of function of one of the CCM proteins, which might not be enough to correct the pathological phenotype, hemorrhagic CCMs
((Zhang J, Abou-Fadel JS. Calm the raging hormone - A new therapeutic strategy involving progesterone-signaling for hemorrhagic CCMs. Vessel Plus. 2021;5:48. Epub 2021 Jul 5. PMID: 35098046; PMCID: PMC8796995.))